Compare BOSC & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | ATOS |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 24.1M |
| IPO Year | 2002 | 2010 |
| Metric | BOSC | ATOS |
|---|---|---|
| Price | $4.72 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 42.0K | 40.7K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $0.53 |
| 52 Week High | $6.72 | $7.56 |
| Indicator | BOSC | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 41.05 |
| Support Level | $4.55 | $2.05 |
| Resistance Level | $4.91 | $2.60 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 42.11 | 0.00 |
BOS Better Online Solutions Ltd is a provider of comprehensive solutions to enterprises, comprised of services, equipment, and custom-made automatic machines. The company manages its business in three reportable divisions: the Supply Chain Solutions Division, the RFID Division, and the Intelligent Robotics Division. The majority of revenue derives from Supply Chain Solutions, which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their component-supply needs. Its geographic areas are Israel, East Asia, India, America, Europe, and the rest of the world. Geographically company derives the majority of its revenue from Israel.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.